Skip to content
Sign in

DGX · NYSE

Quest Diagnostics (DGX) Stock Price & Fundamentals

$476.36+0.52%+$2.45End-of-day price as of Oct 9, 2026

Quest Diagnostics (DGX) closed at $476.36 on Oct 9, 2026, up 0.52% from the previous close of $473.91.

Share price, past year

1Y +32.07%

52-week range $337.95 – $496.35. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$476.36
Sep 30, 2026$467.43
Aug 31, 2026$495.10
Jul 31, 2026$455.63
Jun 30, 2026$432.48
May 29, 2026$413.24
Apr 30, 2026$390.99
Mar 31, 2026$384.06
Feb 27, 2026$381.29
Jan 30, 2026$380.80
Dec 31, 2025$363.46
Nov 28, 2025$352.95
Oct 31, 2025$342.52

Key statistics

Market cap
$52.58B
P/E (TTM)
50.6
EPS (TTM)
$9.42
Revenue (TTM)
$11.56B
Net income (TTM)
$1.06B
Shares outstanding
110.4M
Dividend yield
0.70%
52-week range
$337.95 – $496.35

Quest Diagnostics's market cap is $52.58B, based on a share price of $476.36 and 110.4M shares outstanding as of Jul 15, 2026.

Financials

Quest Diagnostics reported revenue of $11.04B for fiscal 2025, up 11.78% from fiscal 2024.

Quest Diagnostics earned net income of $992.00M in fiscal 2025, a net margin of 9.0%.

Fiscal 2025 revenue was the highest in the 10 years shown.

Annual revenue

FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Annual revenue by fiscal year; the table below lists the values.
Quest Diagnostics annual financials by fiscal year, from SEC filings
Fiscal yearRevenueGrowthNet incomeNet marginEPS (diluted)Free cash flow
FY2025ended Dec 31, 2025$11.04B+11.8%$992.00M9.0%$8.75$1.36B
FY2024ended Dec 31, 2024$9.87B+6.7%$871.00M8.8%$7.69$909.00M
FY2023ended Dec 31, 2023$9.25B−6.4%$854.00M9.2%$7.49$864.00M
FY2022ended Dec 31, 2022$9.88B−8.4%$946.00M9.6%$7.97$1.31B
FY2021ended Dec 31, 2021$10.79B+14.3%$2.00B18.5%$15.55$1.83B
FY2020ended Dec 31, 2020$9.44B+22.2%$1.43B15.2%$10.47$1.59B
FY2019ended Dec 31, 2019$7.73B+2.6%$858.00M11.1%$6.28$843.00M
FY2018ended Dec 31, 2018$7.53B+1.7%$736.00M9.8%$5.29$817.00M
FY2017ended Dec 31, 2017$7.40B+2.6%$772.00M10.4%$5.50$923.00M
FY2016ended Dec 31, 2016$7.21B—$645.00M8.9%$4.51$823.00M
Quest Diagnostics quarterly results
QuarterRevenueNet incomeEPS (diluted)
Q2 FY2026ended Jun 30, 2026$3.04B$320.00M$2.84
Q1 FY2026ended Mar 31, 2026$2.90B$252.00M$2.24
Q4 FY2025ended Dec 31, 2025$2.81B$245.00M$2.18
Q3 FY2025ended Sep 30, 2025$2.82B$245.00M$2.16
Q2 FY2025ended Jun 30, 2025$2.76B$282.00M$2.47
Q1 FY2025ended Mar 31, 2025$2.65B$220.00M$1.94
Q4 FY2024ended Dec 31, 2024$2.62B$222.00M$1.95
Q3 FY2024ended Sep 30, 2024$2.49B$226.00M$1.99

Company profile

Name
Quest Diagnostics Incorporated
Ticker
DGX
Exchange
NYSE
Industry (SEC SIC)
Services-Medical Laboratories
Headquarters
500 Plaza Drive, Secaucus, NJ 07094
Incorporated in
DE
Fiscal year ends
December
SEC CIK
0001022079

Recent SEC filings

Frequently asked questions

What is Quest Diagnostics's stock price?

Quest Diagnostics (DGX) closed at $476.36 on Oct 9, 2026, up 0.52% from the previous close of $473.91.

What is Quest Diagnostics's market cap?

Quest Diagnostics's market cap is $52.58B, based on a share price of $476.36 and 110.4M shares outstanding as of Jul 15, 2026.

How much revenue does Quest Diagnostics make?

Quest Diagnostics reported revenue of $11.04B for fiscal 2025, up 11.78% from fiscal 2024.

What is DGX's P/E ratio?

Quest Diagnostics's price-to-earnings ratio is 50.6, based on trailing twelve-month diluted EPS of $9.42.

Does Quest Diagnostics pay a dividend?

Yes. Quest Diagnostics declared $3.32 per share in dividends over the last four quarters, a yield of 0.70%.

Sources and methodology

Fundamentals come from Quest Diagnostics Incorporated's filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures